COMMUNIQUÉS West-GlobeNewswire

The Ensign Group Acquires Real Estate and Operations in Iowa
02/06/2026
SAN JUAN CAPISTRANO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
The Ensign Group Purchases Memory Care Facility in California
02/06/2026
SAN JUAN CAPISTRANO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]
Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096
02/06/2026
FDA considered the planned HER-096 Phase 2a study design appropriate Study design finalized; approximately 100 patients to be enrolled More than 50% of Phase 2 funding secured or identified Espoo, Finland, 2 June 2026: [...]
Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain
02/06/2026
Dr. Juan Carlos Izpisúa Provides the UGR With the Keys to Science Against Ageing MELBOURNE, Australia, June 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a [...]
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
02/06/2026
Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals Two oral presentations of novel, [...]
Philips announces exchange ratio for 2025 dividend
02/06/2026
June 2, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that the exchange ratio for the dividend for the year 2025 is 1 new common share for every 26.9341 existing common shares. [...]
Transactions in connection with share buy-back program
02/06/2026
Company announcement no. 19 - 26 2 June 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate
02/06/2026
Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals Appointment strengthens confidence in clinical readiness and execution as the [...]
Nanobiotix Joins the Euronext Tech Leaders Index
02/06/2026
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand [...]
Nanobiotix rejoint l'indice Euronext Tech Leaders
02/06/2026
PARIS et CAMBRIDGE, Mass., 02 juin 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
Bavarian Nordic Launches Next Tranche of Share Buy-Back Program
02/06/2026
COPENHAGEN, Denmark, June 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the third and final tranche of the planned buy-back program, under which the Company intends to repurchase own shares for up to DKK 500 [...]
Launch of TechBio firm, Lucera, brings decision intelligence to drug development, making it more predictable, more evidence-grounded, and more efficient
02/06/2026
Launch of TechBio firm, Lucera, brings decision intelligence to drug development, making it more predictable, more evidence-grounded, and more efficient Well-established pharmaceutical technology business of Molecular [...]
Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York
02/06/2026
Leiden, the Netherlands, June 2, 2026: Pharming Group (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the 2026 Jefferies Global Healthcare Conference in New York on June 3-4, [...]
OXB Capital Markets Event
02/06/2026
OXB to demonstrate how its global, multi-vector CDMO platform is positioned to capture growth in the cell and gene therapy market Event to highlight OXB’s proven track record, leading technical capabilities, expanded [...]
Greywolf Therapeutics reports durable clinical responses with first-in-class oral ERAP1 inhibitor GRWD5769 across six solid tumor types
02/06/2026
Data from Phase 1b EMITT-1 trial presented in oral session at ASCO 2026 Annual Meeting First-in-class oral ERAP1 inhibitor demonstrates objective response rates (ORR) of 13–36% across patients with secondary anti-PD-1 [...]
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
02/06/2026
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of [...]
Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
02/06/2026
Daix (France), New York City (New York, United States), le 2 juin 2026 – Inventiva (Euronext Paris et NASDAQ: IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une [...]
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
02/06/2026
Filing acceptance, under priority review, based on phase III data showing giredestrant reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care endocrine therapy 1 Giredestrant [...]
Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea
02/06/2026
Pratteln, Switzerland, June 2, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes that AGAMREE has been granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation by South [...]

Pages